Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors
- 1 June 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 35 (5) , 385-389
Abstract
Malignant glioma is an incurable disease with a relatively short median survival. Several clinical trials have demonstrated that immunotherapy with vaccination is a safe and possibly effective way of prolonging survival. Antibody-based blockade of cytotoxic T-lymphocyte antigen 4 (CTLA-4) ligation on T lymphocytes is associated with enhanced antitumor immunity in animal models of cancer and in patients with advanced melanoma. We hypothesized that sequential therapy with granulocyte-macrophage–colony-stimulating factor (GM-CSF)–expressing whole–glioma-cell vaccination and CTLA-4 blockade is an effective strategy for treating established intracranial gliomas. GL261 glioma cells were injected into the right frontal lobes of syngeneic C57/BL6 mice. At days 3, 6, and 9 after tumor implantation, mice were treated with subcutaneous injection of irradiated GM-CSF–expressing GL261 cells. Mice were also treated with intraperitoneal injection of anti-CTLA-4 monoclonal antibodies (mAbs), either at days 3, 6, and 9 or days 12, 15, and 18. Animals were followed for survival. Splenocytes were harvested at day 22 for use in enzyme-linked immunosorbent spot assays. Early treatment of established intracranial gliomas with high-dose CTLA-4 blockade was associated with increased survival in GL261-bearing mice. Later treatment with anti-CTLA-4 monoclonal antibodies did not significantly improve survival compared with control-treated mice. Early vaccination followed by subsequent CTLA-4 blockade was associated with significantly improved survival versus either treatment alone and intensified tumor-specific immunity as measured by interferon-γ enzyme-linked immunosorbent spot assay. Sequential immunotherapy with GM-CSF–expressing irradiated glioma cells and CTLA-4 blockade synergistically prolongs survival in mice bearing established intracranial gliomas.Keywords
This publication has 25 references indexed in Scilit:
- Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 modelCancer Immunology, Immunotherapy, 2010
- The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant GliomasNeurosurgery Clinics of North America, 2010
- Dendritic Cell Vaccines for Brain TumorsNeurosurgery Clinics of North America, 2010
- Mechanisms of Local Immunoresistance in GliomaNeurosurgery Clinics of North America, 2010
- Glioblastoma-Derived Mechanisms of Systemic ImmunosuppressionNeurosurgery Clinics of North America, 2010
- Preventing Growth of Brain Tumors by Creating a Zone of ResistanceMolecular Therapy, 2008
- Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune DepigmentationJournal of Experimental Medicine, 1999
- Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.1997
- Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.Proceedings of the National Academy of Sciences, 1996
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993